A combined therapy of myo-inositol, d-chiro-inositol and l-methyl folate vs metformin improves women with polycystic ovarian syndrome (pcos): a randomized controlled trial

Introduction: Cardiovascular diseases (CVDs) are a range of blood vessel and heart problems. Cardiovascular complications are any situations that may cause cardiac muscle injury. In terms of mortality rates, cardiovascular disease (CVD) ranks high. Our study’s primary objective was to examine the ef...

Full description

Saved in:
Bibliographic Details
Published inAnnals of medicine and surgery
Main Authors Parvez, Saba, Hameed, Aleena, Siddique, Sadia, Zubair, Amraha, Khan, Auon Zaib, Mumtaz, Hassan, Hasan, Mohammad
Format Journal Article
LanguageEnglish
Published 12.09.2023
Online AccessGet full text

Cover

Loading…
More Information
Summary:Introduction: Cardiovascular diseases (CVDs) are a range of blood vessel and heart problems. Cardiovascular complications are any situations that may cause cardiac muscle injury. In terms of mortality rates, cardiovascular disease (CVD) ranks high. Our study’s primary objective was to examine the effect of polypill on future cardiovascular events in a sizable group of post-MI patients. Methodology: A single-blind, randomized controlled trial was done from June 2021 and July 2022. Randomization assigned 1104 patients (552 males and females) to either the polypill group (100 mg Aspirin, 40 mg Atorvastatin, and 10 mg Ramipril) or standard treatment group. The two sample student’s t- test and chi-square test were used to compare the groups. Results: People in the experimental group were found to age of 43.44±5.78 years old, while control group were 52.98±5.76 years old. Study group systolic blood pressure was 49.32±1.93 mm Hg, compared to control group’s 48.34±10.07 mm Hg. The average range for LDL levels mg/dl in the study group was 10.39, while control group ranged from 29.09 to 27.62. 165 patients (29.89%) died in study group & 247 (44.74%) patients had improved quality of life. 214 (38.76%) patients died in control group and only 127 (23%) patients had improved quality of life. Conclusion: Combination therapy has been shown to reduce the risk of vascular events and overall mortality in a clinical trial. Although it is important to use caution when interpreting treatment impact in observational studies, the findings of this investigation provide credence to the idea that combination therapy is beneficial.
ISSN:2049-0801
2049-0801
DOI:10.1097/MS9.0000000000001111